178 related articles for article (PubMed ID: 38305364)
21. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
22. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
23. Dissecting the effects of GTPase and kinase domain mutations on LRRK2 endosomal localization and activity.
Rinaldi C; Waters CS; Li Z; Kumbier K; Rao L; Nichols RJ; Jacobson MP; Wu LF; Altschuler SJ
Cell Rep; 2023 May; 42(5):112447. PubMed ID: 37141099
[TBL] [Abstract][Full Text] [Related]
24. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
[TBL] [Abstract][Full Text] [Related]
25. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
26. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
[TBL] [Abstract][Full Text] [Related]
27. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
Liu Z; West AB
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
[TBL] [Abstract][Full Text] [Related]
28. LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner
McGrath E; Waschbüsch D; Baker BM; Khan AR
Small GTPases; 2021 Mar; 12(2):133-146. PubMed ID: 31552791
[TBL] [Abstract][Full Text] [Related]
29. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
[TBL] [Abstract][Full Text] [Related]
30. Leucine-rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at pre-synaptic sites.
Marte A; Russo I; Rebosio C; Valente P; Belluzzi E; Pischedda F; Montani C; Lavarello C; Petretto A; Fedele E; Baldelli P; Benfenati F; Piccoli G; Greggio E; Onofri F
J Neurochem; 2019 Aug; 150(3):264-281. PubMed ID: 31148170
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
32. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 Phosphorylation.
Nichols RJ
Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
[TBL] [Abstract][Full Text] [Related]
34. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.
Pungaliya PP; Bai Y; Lipinski K; Anand VS; Sen S; Brown EL; Bates B; Reinhart PH; West AB; Hirst WD; Braithwaite SP
PLoS One; 2010 Oct; 5(10):e13672. PubMed ID: 21060682
[TBL] [Abstract][Full Text] [Related]
36. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).
Mills RD; Mulhern TD; Liu F; Culvenor JG; Cheng HC
Hum Mutat; 2014 Apr; 35(4):395-412. PubMed ID: 24470158
[TBL] [Abstract][Full Text] [Related]
37. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
Park Y; Liao J; Hoang QQ
Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
[TBL] [Abstract][Full Text] [Related]
38. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
[TBL] [Abstract][Full Text] [Related]
39. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.
Muda K; Bertinetti D; Gesellchen F; Hermann JS; von Zweydorf F; Geerlof A; Jacob A; Ueffing M; Gloeckner CJ; Herberg FW
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E34-43. PubMed ID: 24351927
[TBL] [Abstract][Full Text] [Related]
40. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
